Genomic Vision Société Anonyme announced the expansion of its RCA services, emphasising its ongoing commitment to developing its services offers for oncology and drug discovery. Going beyond the standard RCA offerings and bringing tailored solutions, Genomic Vision now can provide new replication parameters like fork speed, analog ratio, fork symmetry, fork stalling and new origin firing. Genomic Vision also offers a new Locus-RCA service, which is attracting growing interest in the scientific community, allowing the assessment of replication dynamic changes in a specific region of the genome, like oncogenes and tumor suppressor genes.

Genomic Vision is proud to deliver tailored RCA services to meet specific needs, demonstrating its commitment to providing customised genomic solutions to its partners, ultimately driving advancements in the pharmaceutical and biotechnology industries. Total sales linked to the RCA service have risen by over 60% in a year. Indeed, between 2022 and 2023, GV achieved an outperformance in the pharmaceutical industry segment, while also seeing constant positive growth in the number of requests from academic laboratories.

Additionally, Genomic Vision's Research & Development team is actively conducting experiments to offer an even more expanded range of parameters and biomarkers for analysis within the RCA framework, further enhancing the capabilities and insights available to its clients.